Brandi Addison, DO
Endocrinology, Diabetes & Metabolism · Corpus Christi, TXNPI 1891115275
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $536,255 of the $646,952 with a category attached, or 82.9%. 53 manufacturers reported payments, led by Lilly USA, LLC at 51.1% of the total. 2025 is the largest year on record at $147,366, more than ten times the $14,242 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,523 payments — averaging $424.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$330K
- Corcept Therapeutics$150K
- Novo Nordisk$98K
- Eli Lilly$18K
- Sanofi-aventis U.S. LLC$18K
- AstraZeneca$18K
- plus $15K from 47 others
Across 5 payments — averaging $981.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$5K
What the payments were for
- Consulting fees$35,3475%
- Speaking & faculty fees$536,25583%
- Travel & lodging$51,6388%
- Food & beverage$23,5384%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$646,952 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 35 | $1,192,867 |
| MounjaroTirzepatide | 577 | $755,007 |
| OzempicSemaglutide | 187 | $239,628 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 170 | $222,263 |
| JardianceEmpagliflozin | 165 | $189,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $134,251 |
| TrulicityDulaglutide | 88 | $125,140 |
| FarxigaDapagliflozin Propanediol | 71 | $76,230 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $58,551 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 49 | $55,858 |
| JanuviaSitagliptin Phosphate | 57 | $44,306 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $29,475 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $27,443 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $27,307 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $22,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $149,658 | $1,192,86735 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $330,392 | $885,615701 claims |
| Novo NordiskOzempic, Rybelsus | $97,569 | $256,624202 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $9,001 | $245,489214 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $18,030 | $222,263170 claims |
| AstraZenecaFarxiga | $17,828 | $76,23071 claims |
| MerckJanuvia, Janumet Xr | $308 | $71,74976 claims |
| AbbVieSynthroid | $102 | $7,29383 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $3,615294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Corpus Christi
- Osvaldo BruscoCorpus Christi$360K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.